Liquid Dosage

Oncology

As a result of growing competition and more stringent regulatory requirements for end-user safety, improving the convenience and ease of administration of parenteral therapeutics is becoming a common strategy for biotechnology and pharmaceutical companies. Manufacturers wishing to gain market share and provide high quality products for healthcare professionals and cancer patients alike are increasingly investing in the development and delivery of liquid dosage forms, freeze-dried products and injectables.

Downloads

GEA Insights

How freeze-dried pet food raises the bar

Pets are family – and owners expect premium, transparent and sustainable nutrition. Freeze-drying, powered by GEA technology, helps pet food makers deliver.

gea enters dax 40

Blueprint for better: How GEA rebuilt itself

Since 2019, GEA has risen from underperformer to DAX member – one of Germany's top 40 listed companies – by fostering entrepreneurship and turning sustainability into a competitive advantage. It reached this milestone in its nearly 145-year history without tailwinds or shortcuts, in a world of compounding crises. This turnaround shows what's possible when purpose and performance align.

Video: GEA's 2025 year in review

This year was a big one for GEA. Can you remember all the milestones and highlights?

Receive news from GEA

Stay in touch with GEA innovations and stories by signing up for news from GEA.

Need assistance?

We are here to help! With just a few details we will be able to respond to your inquiry.